SUSAN BLANEY to Topotecan
This is a "connection" page, showing publications SUSAN BLANEY has written about Topotecan.
Connection Strength
1.697
-
A phase-1 pharmacokinetic optimal dosing study of intraventricular topotecan for children with neoplastic meningitis: a Pediatric Brain Tumor Consortium study. Pediatr Blood Cancer. 2013 Apr; 60(4):627-32.
Score: 0.412
-
Phase 2 clinical trial of intrathecal topotecan in children with refractory leptomeningeal leukemia: a Children's Oncology Group trial (P9962). Pediatr Blood Cancer. 2012 Mar; 58(3):362-5.
Score: 0.383
-
Phase I clinical trial of intrathecal topotecan in patients with neoplastic meningitis. J Clin Oncol. 2003 Jan 01; 21(1):143-7.
Score: 0.210
-
The development of camptothecin analogs in childhood cancers. Oncologist. 2001; 6(6):506-16.
Score: 0.183
-
Phase II trial of topotecan administered as 72-hour continuous infusion in children with refractory solid tumors: a collaborative Pediatric Branch, National Cancer Institute, and Children's Cancer Group Study. Clin Cancer Res. 1998 Feb; 4(2):357-60.
Score: 0.149
-
Topotecan by 21-day continuous infusion in children with relapsed or refractory solid tumors: a Children's Oncology Group study. Pediatr Blood Cancer. 2006 Nov; 47(6):790-4.
Score: 0.068
-
New agents for intrathecal administration. Cancer Invest. 2006 Aug-Sep; 24(5):528-34.
Score: 0.067
-
Safety, tolerability and pharmacokinetics of crizotinib in combination with cytotoxic chemotherapy for pediatric patients with refractory solid tumors or anaplastic large cell lymphoma (ALCL): a Children's Oncology Group phase 1 consortium study (ADVL1212). Cancer Chemother Pharmacol. 2020 12; 86(6):829-840.
Score: 0.045
-
New cytotoxic drugs for intrathecal administration. J Neurooncol. 1998 Jun-Jul; 38(2-3):219-23.
Score: 0.038
-
Phase II evaluation of topotecan for pediatric central nervous system tumors. Cancer. 1996 Aug 01; 78(3):527-31.
Score: 0.034
-
Intrathecal administration of topotecan in nonhuman primates. Cancer Chemother Pharmacol. 1995; 36(2):121-4.
Score: 0.030
-
Pediatric phase I trial and pharmacokinetic study of topotecan administered as a 24-hour continuous infusion. Cancer Res. 1993 Mar 01; 53(5):1032-6.
Score: 0.027
-
Plasma and cerebrospinal fluid pharmacokinetic study of topotecan in nonhuman primates. Cancer Res. 1993 Feb 15; 53(4):725-7.
Score: 0.026
-
A phase II window trial of procarbazine and topotecan in children with high-grade glioma: a report from the children's oncology group. J Neurooncol. 2006 Apr; 77(2):193-8.
Score: 0.016
-
A pharmacokinetic model of topotecan clearance from plasma and cerebrospinal fluid. Cancer Res. 1994 Oct 01; 54(19):5118-22.
Score: 0.007